Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapy
Acta Pharmaceutica Sinica B
; (6): 1069-1082, 2021.
Article
en En
| WPRIM
| ID: wpr-881185
Biblioteca responsable:
WPRO
ABSTRACT
The intracellular retention of nanotherapeutics is essential for their therapeutic activity. The immobilization of nanotherapeutics inside target cell types can regulate various cell behaviors. However, strategies for the intracellular immobilization of nanoparticles are limited. Herein, a cisplatin prodrug was synthesized and utilized as a glutathione (GSH)-activated linker to induce aggregation of the cisplatin prodrug/IR820/docetaxel nanoassembly. The nanoassembly has been reprogrammed with peptide-containing moieties for tumor-targeting and PD-1/PD-L1 blockade. The aggregation of the nanoassemblies is dependent on GSH concentration. Evaluations
Texto completo:
1
Base de datos:
WPRIM
Idioma:
En
Revista:
Acta Pharmaceutica Sinica B
Año:
2021
Tipo del documento:
Article